# US 2021/0228613 A1 · Formulations containing triazinones and iron with a low amount of free iron ions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228613 A1
- Document ID: US20210228613A1
- Status: Published application
- Kind: A1
- Application number: 15/734,860
- Filed: 2019-05-29
- Published: 2021-07-29
- Earliest claimed: 2018-06-05
- Assignees: Bayer Animal Health GmbH
- Applicants: Bayer Animal Health GmbH
- Inventors: Stefan Hofmann; Wolfgang Jiritschka
- Web page: https://patentgrep.com/patent/US20210228613A1

## CPC

- A23L 33/165: Complexes or chelates
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A23K 50/60: for weanlings
- A23L 33/16: Inorganic salts, minerals or trace elements
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 33/26: Iron; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER

## Abstract

Formulations containing triazinones, selected from toltrazuril, ponazuril and diclazuril, a polynuclear iron(III) polysaccharide complex compound which are suitable for the simultaneous control of coccidiosis and anaemic states in animals and which exhibit a low amount of free iron ions even after storage, while the formulations comprises Ca2+ and Na+ in a molar ratio of Ca2+:Na+ from ≥0 to ≤3. In one embodiment the triazinone is toltrazuril and the polynuclear iron(III) polysaccharide complex compound is iron(III) dextran glucoheptonate.

## Claims

### Claim 1

A formulation comprising a triazinone selected from the list consisting of toltrazuril, ponazuril and diclazuril, a polynuclear iron(III)polysaccharide complex compound, and a molar ratio of Ca2+ to Na+ from ≥0 to ≤3, with the exception of sodium propionate and/or sodium benzoate being the sole source of Na+ in the formulation when the molar ratio of Ca2+ to Na+ is 0.

### Claim 2 (depends on 1)

A formulation according to claim 1, with the further exception of those formulations being selected from the list consisting of
a. a formulation, consisting of 3.5% toltrazuril, 17.8% of iron (as Gleptoferron), 0.1% of sorbitan monooleate, 10% diethylene glycol monoethyl ether, 1% of sodium chloride, and Water ad 100%,
b. a formulation, consisting of 3.5% toltrazuril, 19.3% of iron (as Gleptoferron), 0.3% of Propylene Glycol Monolaurate, 0.1% of copolymer Polyoxyl 35-hydrogenated castor oil, 1% Sodium Chloride, and Water ad 100%,
c. a formulation, consisting of 4.2% toltrazuril, 13.5% of iron (as Gleptoferron), 0.1% Sodium Docusate, 0.1% silicone emulsion, l.5% sodium chloride, and Water ad 100%,
d. a formulation, consisting of 4.2% toltrazuril, 13.5% of iron (as Gleptoferron), 0.1% Sodium Docusate, 5% diethylene glycol monoeethyl ether, 0.1% silicone emulsion, 1% sodium chloride, and Water ad 100%,
e. a formulation, consisting of 4.2% toltrazuril, 13.5% of iron (as Gleptoferron), 0.6% Phenole, 0.2% Sodium Docusate, 0.1% simethicone emulsion USP 30%, 0.5% colloidal silicone dioxide, 1% povidone, 0.5% sodium chloride, and Water ad 100%,
f. a formulation, consisting of 4.2% toltrazuril, 13.5% of iron (as Gleptoferron), 0.6% Phenole, 0.2% Sodium Docusate, 0.1% simethicone emulsion USP 30%, 0.5% colloidal silicone dioxide, 1% povidone, 1% sodium chloride, and Water ad 100%,
g. a formulation, consisting of 4.2% toltrazuril, 13.5% of iron (as Gleptoferron), 0.6% Phenole, 0.1% Sodium Docusate, 0.1% simethicone emulsion USP 30%, 0.5% colloidal silicone dioxide, 1% povidone, 1% sodium chloride, and Water ad 100%,
h. a formulation, consisting of 2.9% toltrazuril, 18.8% of iron (as Gleptoferron), 0.6% Phenole, 0.1% Sodium Docusate, 0.1% simethicone emulsion USP 30%, 0.5% colloidal silicone dioxide, 1% povidone, 1% sodium chloride, and Water ad 100%,
i. a formulation, consisting of 2.9% toltrazuril, 18.8% of iron (as Gleptoferron), 0.3% of sorbitan monooleate, 0.1% of copolymer 15 Polyoxyl 35 -hydrogenated castor oil, 1.5% of sodium chloride and water,
j. a formulation, consisting of 4.2% toltrazuril, 13.5% of iron (as Gleptoferron), 0.3% of sorbitan monooleate, 0.1% of copolymer Polyoxyl 35-hydrogenated castor oil, 1.5% of sodium chloride and water, and
k. a formulation, consisting of 4.2% toltrazuril, 13.5% of iron (as Gleptoferron), 1% of sodium chloride, 1% of polyvinylpyrrolidone, 0.6% of phenol, 0.5% of colloidal silicon dioxide, 0.1% of sodium docusate, 0.1% of simethicon emulsion and water.

### Claim 3 (depends on 1)

The formulation according to claim 1, wherein the formulation has a molar ratio of Ca2+ to Na+ from >0 to ≤3.

### Claim 4 (depends on 1)

The formulation according to claim 1, wherein Ca2+ and Na+ are present as their respective chloride salts.

### Claim 5 (depends on 4)

The formulation according to claim 4, wherein the total content of CaCl2 and NaCl is from ≥0.1% (m/V) to ≥3% (m/V).

### Claim 6 (depends on 1)

The formulation according to claim 1, wherein active iron in the form of the polynuclear iron(III) polysaccharide complex compound is present from ≥10% (m/V) to ≤30% (m/V).

### Claim 7 (depends on 1)

The formulation according to claim 1, wherein the triazinone is toltrazuril and the polynuclear iron(III) polysaccharide complex compound is iron(III)dextran glucoheptonate.

### Claim 8 (depends on 1)

The formulation according to claim 1, wherein the formulation also comprises at least one non-ionic surfactant.

### Claim 9 (depends on 1)

A method of simultaneous treatment of a coccidial infection and an iron deficiency, comprising administering to a mammal in need thereof a formulation according to claim 1.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the formulation is administered by parenteral application.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the formulation is administered by injection.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the mammal is a piglet in the period from birth to 10 days after birth.

### Claim 13

A method of imparting a content of dissolved free iron of ≤3500 ppm in a formulation comprising a triazinone selected from the list consisting of toltrazuril, ponazuril and diclazuril, and a polynuclear iron(III) polysaccharide complex compound, after storage at a temperature of ≥20° C. to ≤40° C. for at least 6 months, the method comprising providing in the formulation Ca2+ and Na+ in a molar ratio of Ca2+ to Na+ from ≥0 to ≤3.
